DEPARTMENT OF RHEUMATOLOGY

Similar documents
RHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center

Overview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology

ArLAR 2018, the Pan Arab Rheumatology Conference in conjunction with the 1st OSR meeting 23 to 25 February 2018, Muscat, Oman.

Financial Report. Moving Together

Rheumatology Suggested Reading List. Compiled by Rebecca Sharim MD. Updated: 4/6/17

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)

Kelley's Textbook of Rheumatology. 2 Volume Set. Text with Internet Access Code for Premium Consult Edition

Essential Rheumatology. Dr Ellen Bruce Consultant Rheumatologist CMFT

JuvenileIdiopathicArthritis. Dr Johan Siebert

2/23/18. Disclosures. Rheumatic Diseases of Childhood. Making Room for Rheumatology. I have nothing to disclose. James J.

Effective Health Care Program

Coverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication

A CRP B FBC C LFT D blood culture E uric acid

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

Rheumatologic Laboratory Testing and Common Hematological Drugs. September 10, 2013 Dr. Jeffrey C. Hoschek, MD, FAAP

CONTENT OUTLINE. Pediatric Rheumatology

A. Smržová. III. Interní klinika FN Olomouc nefrologická, revmatologická a endokrinologická

Abatacept (Orencia) for active rheumatoid arthritis. August 2009

Rheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW POLAND prof. Małgorzata Wisłowska

Jeopardy. What s the rash? $100 $100 $100 $100 $100 $200 $200 $200 $200 $200 $300 $300 $300 $300 $300 $400 $400 $400 $400 $400

Biologics in rheumatic diseases

The Hospital for Sick Children Technology Assessment at SickKids (TASK)

APPLICATION FOR SPECIAL AUTHORITY. Subsidy for Tocilizumab

Competency Based Curriculum

Year In Review: VasculitisPers. Disclosures. Learning Objectives. none 4/16/2018. Describe new medications for the treatment of vasculitis

Corporate Medical Policy

Juvenile Idiopathic Arthritis (JIA)

REFERRAL GUIDELINES: RHEUMATOLOGY

ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION

Corporate Medical Policy

Prior Authorization Policy

BIOLOGIC THERAPY : A NEW OPTION FOR TREATMENT JUVENILE IDIOPATHIC ARTHRITIS DR TON THAT HOANG

Where has SARA gone? Prof. David Kane Consultant Rheumatologist Beacon & Tallaght Hospitals. Clinical Professor in Rheumatology Trinity College Dublin

Rheumatoid Arthritis

Corporate Medical Policy

Center for Evidence-based Policy

4/16/2018. Demystifying weakness: how to approach refractory myositis. Objectives. Disclosures. Off-label uses for medications will be discussed

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 08/19/14 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Ad-Hoc Rheumatology Subcommittee of PTAC meeting held 8 March. (minutes for web publishing)

Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximababda)

DRAFT FOR POC BOARD Clinical Commissioning Policy Proposition: Rituximab in Connective Tissue Disease associated Interstitial Lung Disease (adults)

Horizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.

Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda)

ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION

Medical Coverage Guidelines are subject to change as new information becomes available.

Diagnostic Tests in Rheumatic Disease: What s Old, What s New & What s Useful? COPYRIGHT

Skin cancers in patients treated with immunomodulating drugs. Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France

Small Vessel Vasculitis

UNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS

University of Bristol - Explore Bristol Research. Peer reviewed version. Link to published version (if available): / X.

Staging of Type 1 Diabetes: Clinical Implications. April Deborah Hefty, MN, RN, CDE.

SMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018

ACTEMRA (tocilizumab)

Orencia (abatacept) for Rheumatoid Arthritis. Media backgrounder

Medication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014

RITUXAN (rituximab), NONONCOLOGIC USES

Horizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.

Index. Note: Page numbers of article titles are in boldface type.

Rheumatology 101 A Pediatrician s Guide

Remicade (infliximab) DRUG.00002

Learning Objectives and Assessment Methodologies Combined Medicine-Pediatrics Rheumatology Elective

CENTRAL NERVOUS SYSTEM VASCULITIS

PHARMACY POLICY STATEMENT Ohio Medicaid

New Drugs for Uveitis. Medical Eye Unit St Thomas Hospital

Autoantibodies in the Idiopathic Inflammatory Myopathies

Index. Note: Page numbers of article titles are in boldface type.

Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation

PAEDIATRIC VASCULITIS

Immune Modulating Drugs Prior Authorization Request Form

Is it Autoimmune or NOT! Presented to AONP! October 2015!

Juvenile Spondyloarthritis / Enthesitis Related Arthritis (SpA-ERA)

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

Primary Results Citation 2

INFLIXIMAB (REMICADE, INFLECTRA, RENFLEXIS )

TAKAYASU S ARTERITIS. Second-stage symptoms include:

ACTEMRA (tocilizumab)

Emerging Therapies for Lung Fibrosis. Helen Garthwaite Respiratory Registrar/ Clinical Research Fellow

HORIZON SCANNING: PAEDIATRIC RHEUMATOLOGY UPATE SEPTEMBER 2011

Infliximab/Infliximab-dyyb DRUG.00002

Undifferentiated Connective Tissue Disease and Overlap Syndromes. Mark S. Box, MD

(minutes for web publishing)

Nausheen Khuddus, MD Melissa Elder, MD, PhD

Decision relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin)

Dr Daniel Ching. Rheumatology Therapeutic Clinical Trials Centre Timaru

Curricular Components for Rheumatology EPA

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC

Medication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013

Orencia (abatacept) DRUG.00040

Vasculitis in primary connective tissue diseases

3 rd Appraisal Committee meeting, 28 February 2017 Committee D

oimmune_disease

GRANULOMATOSIS WITH POLYANGIITIS

TOCILIZUMAB FOR DIFFICULT TO TREAT IDIOPATHIC RETROPERITONEAL FIBROSIS. A PILOT TRIAL

Clinical Commissioning Policy: Rituximab For ANCA Vasculitis. December Reference : NHSCB/ A3C/1a

HORIZON SCANNING: PAEDIATRIC RHEUMATOLOGY UPATE FEBRUARY 2011

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

Differential diagnostics in Rheumatology

ANCA+ VASCULITIDES CYCAZAREM,

Pharmacy Prior Authorization

Transcription:

DEPARTMENT OF RHEUMATOLOGY PG Teaching Schedule Theory (8 30 am to 9am) DATE TOPIC PRESENTER FACULTY 01/10/16 Approach to Arthritis Dr. Sandeep Dr. Suma Balan 03/10/16 Cardiovascular risk in Rheumatic Disease Dr. Sandeep Dr. Suma Balan 04/10/16 Diagnostic tests and procedures in Rheumatic Disease Dr. Sandeep Dr. Suma Balan 05/10/16 Imaging Modalities in Rheumatic Disease Dr. Sandeep Dr. Suma Balan 01/11/16 Early Arthritis Dr. Vishnu Dr.Mithun C B 02/11/16 Etiology and Pathognesis Dr. Vishnu Dr.Mithun C B 03/11/16 Undifferentiated Arthritis Dr. Vishnu Dr.Mithun C B 04/11/16 Reactive Arthritis Dr. Vishnu Dr.Mithun C B 01/12/16 Early Rheumatoid Arthritis Dr. Sandeep Dr.Mithun C B 02/12/16 Clinical Features Dr. Sandeep Dr.Mithun C B 03/12/16 Treatment of Rheumatoid Arthritis Dr. Sandeep Dr.Mithun C B 02/01/17 Late Rheumatoid Arthritis Dr.Vishnu Dr. Jyothi Srikanth 03/01/17 Overlap Syndrome Dr.Vishnu Dr. Jyothi Srikanth 04/01/17 Sjogrn Syndrome Dr.Vishnu Dr. Jyothi Srikanth

SEMINARS (3pm to 4pm) DATE TOPIC PRESENTER FACULTY 03/10/16 Nail Fold Cappilaroscopy Dr. Sarah Dr. Suma Balan 10/10/16 Dermatomyositis Dr. Veena Dr.Mithun C B 17/10/16 Behcet s Disease Dr. Sandeep Dr. Suma Balan 24/10/16 Sarcoidosis Dr.Vishnu Dr. Jyothi Srikanth 31/10/16 Juvenile Idiopathic Arthritis Dr. Sandeep Dr. Vishal Marwaha 07/11/16 Approach to Gangrene Dr. Vishnu Dr. Suma Balan 14/11/16 Interpretation of lab investigations in Dr.Sandeep Dr. Mithun C B autoimmune disease 21/11/16 Methotrexate Mechanism of Action Dr. Vishnu Dr. Vishal Marwaha 28/11/16 Interpretation of labs Dr. Sandeep Dr. Suma Balan 05/12/16 Methotrexate in Pregnancy Dr. Vishnu Dr. Jyothi Srikanth 12/12/16 ANA Part one Dr. Sandeep 19/12/16 ANA Part two Dr. Vishnu 26/12/16 ANA Part three Dr. Sandeep 02/0116 Methotrexate Dosing,Oral vs Sub cutaneous route, Perioperative adjustments. 09/01/17 Joint examination and Intra articular injection Shoulder joint. 16/01/17 Joint examination and Intra articular injection elbow joint. 23/01/17 Joint examination and Intra articular injection wrist joint Dr. Vishnu Dr. Sandeep Dr. Vishnu Dr. Sandeep Dr. Suma Balan Dr. Jyothi Srikanth Dr. Vishal Marwaha Dr. Suma Balan

30/01/17 Joint examination and Intra articular injection- metacarpsl joint Dr. Vishnu CASE PRESENTATIONS (8:30 am to 9:30am) DATE DIAGNOSIS PRESENTER FACULTY 05/10/16 Axial SPA Dr. Vishnu Dr. Suma Balan 12/10/16 Behcet s disease Dr. Sandeep Dr. MIthun C B 19/10/16 Refractory RA Dr. Vishnu Dr. Suma Balan 26/10/16 Sarcoidosis Dr. Sandeep Dr. Jyothi Srikanth 02/11/16 Sarcoidosis Dr. Vishnu Dr. Vishal Marwaha 09/11/16 Wegner s Granulomatosis relapse Dr. Sandeep Dr. Mithun C B 16/11/16 Hypercalcemia with Purpura Dr.Vishnu Dr. Mithun C B 23/11/16 Churg Strauss syndrome Dr. Sandeep Dr. Suma Balan 30/11/16 Undifferentiated Connective Tissue Disease Dr.Vishnu Dr. Jyothi Srikanth 07/12/16 Lupus Nephritis Dr. Sandeep Dr. Vishal Marwaha 14/12/16 Chronic Sarcoidosis Dr.Vishnu Dr. Jyothi Srikanth 21/12/16 Behcets syndrome Dr. Sandeep Dr. Vishal Marwaha 28/12/16 Juvenile Idiopathic Arthritis Dr.Vishnu Dr. Mithun C B 04/01/17 Sine Scleroderma Dr. Sandeep Dr. Suma Balan 11/01/17 Rheumatoid Arthritis Dr.Vishnu Dr. Jyothi Srikanth 18/01/17 Henoch Schonlein purpura Dr. Sandeep Dr. Vishal Marwaha 25/01/17 Sarcoidosis with ocular and lung involvement Dr.Vishnu Dr. Mithun C B

BEDSIDE TEACHING (4pm to 5pm) DATE TOPIC FACULTY 06/10/16 Behcet s Disease Dr Vishal Marwaha 13/10/16 Henoch Schonlein purpura Dr. Mithun CB 20/10/16 Oligo-Articular JIA Dr. Suma Balan 27/10/16 Peripheral Spondyloarthopathy Dr. Jyothi S. 03/11/16 Polyarticular JIA Dr. Suma Balan 10/11/16 Axial Spondyloarthritis - Refractory disease Dr. Mithun CB 17/11/16 Sine Scleroderma with Severe PAH -RV dysfunction Dr Vishal Marwaha 01/12/16 Idiopathic Sceleritis Dr. Mithun CB 08/12/16 Systemic Onset JIA Dr. Suma 15/12/16 Dermatomyositis Dr. Jyothi S. 22/12/16 Kawasaki s Disaease Dr. Suma 29/12/16 Refractory Polymyositis Dr. Mithun CB 05/01/17 Limited systemic sclerosis with severe Raynaud's Dr Vishal Marwaha phenomenon 12/01/17 RA with Vascultis 19/01/17 PUO with Polyarthritis under evaluation Dr Vishal Marwaha

JOURNAL CLUBS (4pm to 5pm) DATE TOPIC FACULTY 04/10/16 Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related ILD (SLS II): a RCT parallel group trial 11/10/16 BSR and BHPR guidelines for the treatment of systemic sclerosis. 25/10/16 Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med. 2016 Dr Suma Balam Dr Jyothi Srikanth 01/11/16 Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A RCT; JAMA. 2016 Aug Dr Vishal Marwaha 15/11/16 Effect of Tabalumab in patients with RA who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, doubleblind study - Ann Rheum Dis. 2015 22/11/16 Arthritis & Rheumatology article: Lesinurad Combined With Allopurinol: A Randomized, Double- Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol Dr Suma Balam 06/12/16 Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis - PRECISION Trial 13/12/16 Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double- Dr Jyothi Srikanth Dr Vishal Marwaha

Blind, Placebo-Controlled Trial 27/12/16 Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months 03/01/17 Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis 10/01/17 Non TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial 31/01/17 Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention: A Systematic Review and Meta-analysis. Dr Suma Balam Dr Jyothi Srikanth PROCEDURES MONTH PROCEDURES Oct-2016 166 Nov-2016 155 Dec-2016 155 Jan-2017 167 Vishal Marwaha, HOD Department Of Rheumatology AIMS Kochi